趋化因子CXCL5在前列腺癌中的表达和意义
|
摘要
研究背景:前列腺癌(prostate cancer)是常见的男性泌尿系恶性肿瘤,近年来其发病率呈明显增长趋势,已成为威胁男性健康的常见疾病之一。目前,前列腺癌的发生机制尚不清楚,各种可能的影响因素仍在探索中。炎症与肿瘤的关系逐渐成为研究的热点,趋化因子作为炎症因子中的重要组成部分,其在各种肿瘤发生发展过程中的作用已被人们所关注。研究表明,趋化因子不仅仅参与了免疫反应,它也是肿瘤的发生、发展、侵袭及转移的重要调节因子之一。有些趋化因子能促进肿瘤的增殖,促进血管生成,诱导肿瘤细胞移动和粘附内皮细胞,加速肿瘤的扩散和转移;有些趋化因子能抑制肿瘤细胞生长,抑制血管生成,激发机体特异性和非特异性免疫应答,抑制肿瘤的生长和转移。CXCL5(CXC chemokine Ligand-5,CXC趋化因子配体-5)是促血管生成性CXC趋化因子家族中的一员,可由上皮细胞、内皮细胞、成纤维细胞、中性粒细胞、单核细胞和巨噬细胞产生,具有很强的粒细胞趋化作用。已有实验证实,CXCL5可促进非小细胞肺癌、胃癌及子宫内膜癌等肿瘤的发生、发展和转移。CXCL5在前列腺癌中的表达情况尚少有文献报道。本实验拟用免疫组化的方法检测CXCL5在前列腺癌的表达情况,以期探讨CXCL5在前列腺癌发生、发展及转移中的作用,为前列腺癌发生机制的研究提供实验依据。
目的:观察CXCL5在前列腺癌中的表达,分析其与前列腺癌病理分级、临床分期及肿瘤转移的关系,探讨CXCL5在前列腺癌发生、发展、侵袭及转移中的作用。
方法:收集中南大学湘雅医院病理科2003年10月-2008年10月间诊断为前列腺癌、PIN(prostate intraepithelial neoplasia,前列腺上皮内瘤)及前列腺增生的病例及其临床病理资料(前列腺癌41例,PIN 6例,前列腺增生14例),复阅HE染色病理组织切片。采用免疫组织化学SP法检测前列腺癌、PIN、及前列腺增生中CXCL5的表达,染色后阅片、评分,对比其在各组之间表达的差异,分析其表达水平与前列腺癌临床病理参数的关系。采用成组t检验和单因素方差分析进行统计学分析,P＜0.05认为有统计学意义。
结果:免疫组织化学结果显示CXCL5在41例前列腺癌组(染色评分10.02±2.055分)中表达,明显高于前列腺非癌组(染色评分4.45±1.317分)(P＜0.05)。在不同病理分级前列腺癌组织中,从高分化组到低分化组CXCL5染色强度逐渐加深,染色评分逐渐升高,各组间比较有差异显著性意义(P＜0.05)。CXCL5在Whitmore-Jewett分期系统C+D期组的表达明显高于A+B期组(P＜0.05)。CXCL5在转移性前列腺癌组中的表达明显高于无转移组(P＜0.05)。
结论:CXCL5在前列腺癌组织中的表达高于前列腺增生和PIN。CXCL5的表达与前列腺癌病理分级恶性程度、临床分期、转移呈正相关。CXCL5可能参与了前列腺癌的发生、发展与转移过程。
Background: Prostate cancer is one of the most prevalent malignacies affecting men worldwide. And the number of afflicted men is increasing rapidly. Recent studies indicate that Chemokines, a family of inflammation factors, are important mediators in tumorogenesis, progression, invasion and metastasis of prostate cancer. CXCL5 is a proangiogenic CXC-type chemokine that is an inflammatory mediator and a powerful attractant for granulocytic immune cells. CXCL5 is secreted by several cell types, including epithelial cells, endothelial cells, fibroblasts, neutrophils, monocytes, and macrophages. It has been shown that CXCL5 could promote the growth and metastasis of non-small cell lung cancer, gastric cancer and endometrial cancer. The current study is intended to observe the expression of CXCL5 in prostate cancer, and explore the role CXCL5 plays in the progression and metastasis of prostate cancer.
Objective: Investigate the expression of CXCL5 in human prostate cancer. Analysis the expression result with the pathologic grading of cancer, clinical stage and tumor metastasis. And explore the role CXCL5 plays in the progression and metastasis of prostate cancer.
Methods: Collect the cases of prostate cancer, PIN and benign prostatic hyperplasia from Oct, 2003 to Oct, 2008 in pathological department of Xiangya Hospital of Central South University. The expression of CXCL5 in prostate cancer (n=41 tissues), benign prostatic hyperplasia (n=14 tissues) and PIN (n=6 tissues) were detected by immunohistochemistry SP method. The CXCL5 expression was compared among these different tissues. The relationship between CXCL5 expression and related clinicopathologic features was statistically analyzed.
Results: The immunohistochemistry detection of CXCL5 in paraffin slides indicates that the staining scores of CXCL5 in prostate cancer(10.02±2.055) was significant higher than that in non-cancer tissue(4.45±1.317) (P<0.05). The cases were classified by the Whitmore-Jewett staging system and graded according to Gleason grading system. The expression of CXCL5 was associated with pathological grades and clinical stages. The staining scores of CXCL5 in C+D stages were significant higher than that in A+B stages(P<0.05). The expression of CXCL5 in metastatic prostate cancer was higher than that in prostate cancer without metastasis (P<0.05).
Conclusion: The expression of CXCL5 in prostate cancer was significant higher than that in benign prostatic hyperplasia and prostate intraepithelial neoplasia. And it was associated with pathological grade , clinical stage and tumor metastasis. CXCL5 may play a role in the progression and metastasis of prostate cancer.
目的:观察CXCL5在前列腺癌中的表达,分析其与前列腺癌病理分级、临床分期及肿瘤转移的关系,探讨CXCL5在前列腺癌发生、发展、侵袭及转移中的作用。
方法:收集中南大学湘雅医院病理科2003年10月-2008年10月间诊断为前列腺癌、PIN(prostate intraepithelial neoplasia,前列腺上皮内瘤)及前列腺增生的病例及其临床病理资料(前列腺癌41例,PIN 6例,前列腺增生14例),复阅HE染色病理组织切片。采用免疫组织化学SP法检测前列腺癌、PIN、及前列腺增生中CXCL5的表达,染色后阅片、评分,对比其在各组之间表达的差异,分析其表达水平与前列腺癌临床病理参数的关系。采用成组t检验和单因素方差分析进行统计学分析,P＜0.05认为有统计学意义。
结果:免疫组织化学结果显示CXCL5在41例前列腺癌组(染色评分10.02±2.055分)中表达,明显高于前列腺非癌组(染色评分4.45±1.317分)(P＜0.05)。在不同病理分级前列腺癌组织中,从高分化组到低分化组CXCL5染色强度逐渐加深,染色评分逐渐升高,各组间比较有差异显著性意义(P＜0.05)。CXCL5在Whitmore-Jewett分期系统C+D期组的表达明显高于A+B期组(P＜0.05)。CXCL5在转移性前列腺癌组中的表达明显高于无转移组(P＜0.05)。
结论:CXCL5在前列腺癌组织中的表达高于前列腺增生和PIN。CXCL5的表达与前列腺癌病理分级恶性程度、临床分期、转移呈正相关。CXCL5可能参与了前列腺癌的发生、发展与转移过程。
Background: Prostate cancer is one of the most prevalent malignacies affecting men worldwide. And the number of afflicted men is increasing rapidly. Recent studies indicate that Chemokines, a family of inflammation factors, are important mediators in tumorogenesis, progression, invasion and metastasis of prostate cancer. CXCL5 is a proangiogenic CXC-type chemokine that is an inflammatory mediator and a powerful attractant for granulocytic immune cells. CXCL5 is secreted by several cell types, including epithelial cells, endothelial cells, fibroblasts, neutrophils, monocytes, and macrophages. It has been shown that CXCL5 could promote the growth and metastasis of non-small cell lung cancer, gastric cancer and endometrial cancer. The current study is intended to observe the expression of CXCL5 in prostate cancer, and explore the role CXCL5 plays in the progression and metastasis of prostate cancer.
Objective: Investigate the expression of CXCL5 in human prostate cancer. Analysis the expression result with the pathologic grading of cancer, clinical stage and tumor metastasis. And explore the role CXCL5 plays in the progression and metastasis of prostate cancer.
Methods: Collect the cases of prostate cancer, PIN and benign prostatic hyperplasia from Oct, 2003 to Oct, 2008 in pathological department of Xiangya Hospital of Central South University. The expression of CXCL5 in prostate cancer (n=41 tissues), benign prostatic hyperplasia (n=14 tissues) and PIN (n=6 tissues) were detected by immunohistochemistry SP method. The CXCL5 expression was compared among these different tissues. The relationship between CXCL5 expression and related clinicopathologic features was statistically analyzed.
Results: The immunohistochemistry detection of CXCL5 in paraffin slides indicates that the staining scores of CXCL5 in prostate cancer(10.02±2.055) was significant higher than that in non-cancer tissue(4.45±1.317) (P<0.05). The cases were classified by the Whitmore-Jewett staging system and graded according to Gleason grading system. The expression of CXCL5 was associated with pathological grades and clinical stages. The staining scores of CXCL5 in C+D stages were significant higher than that in A+B stages(P<0.05). The expression of CXCL5 in metastatic prostate cancer was higher than that in prostate cancer without metastasis (P<0.05).
Conclusion: The expression of CXCL5 in prostate cancer was significant higher than that in benign prostatic hyperplasia and prostate intraepithelial neoplasia. And it was associated with pathological grade , clinical stage and tumor metastasis. CXCL5 may play a role in the progression and metastasis of prostate cancer.
引文
[1]Ahmedin Jemal,Rebecca Siegel,et al.Cancer Statistics,2008.CA Cancer J Clin,2008,58:71-96.
[2]孙颖浩.前列腺癌诊断与治疗现状.实用老年医学,2005,19(4):179-11.
[3]Ajuebor MN,Swain MG,Perretti M,et al.Chemokines as novel therapeutic target s in inflammatory diseases.Biochem Pharmacol,2002,63(7):1191.
[4]Alain P.Vicari,Christophe Caux.Chemokines in cancer.Cytokine & Growth Factor Reviews,2002,13:143-154.
[5]Walz A,Burgener R,Car B,Baggiolini M,Kunkel SL,Strieter RM.Structure and neutrophil-activating properties of a novel inflammatory peptide(ENA-78)with homology to interleukin 8.J Exp Med.1991,174(6):1355-1362.
[6]Arenberg DA,Keane MP,et al.Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer.J Clin Invest,1998,102(3):465-472.
[7]Frick VO,et al.Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases.Pancreatology,2008,8(4-5):488-497.
[8]Wong YF,Cheung TH,Lo KW,Yim SF,Siu NS,Chan SC,Ho TW,Wong KW,Yu MY,Wang VW,et al.Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling.Oncogene,2007,26:1971-1982.
[9]Miyazaki H,Patel V,Wang H,Ensley JF,Gutkind JS,and Yeudall WA.Growth factor-sensitive molecular targets identified in primary and metastatic head and neck squamous cell carcinoma using microarray analysis.Oral Oncol,2006,42(3):240-256.
[10]Miyazaki H,Patel V,Wang H,Edmunds RK,Gutkind JS,and Yeudall WA.Down-regulation of CXCL5 inhibits squamous carcinogenesis.Cancer Res,2006,66(8):4279-4284.
[11]Park JY,Park KH,Bang S,Kim MH,Lee JE,Gang J,Koh SS,and Song SY,CXCL5 overexpression is associated with late stage gastric cancer.J Cancer Res Clin Oncol,2007,133(11):835-840.
[12] Folkman J. Tumor angiogenesis: therapeutic implication. N Engl J Med, 1971, 285 (21): 1182-1186.
[13] Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 1994, 79 (2): 185-188.
[14] Folkman J. The vascularization of tumors. Sci Am, 1976,234(5): 58-64, 70-73.
[15] Folkman J. Fighting cancer by attacking its blood supply. Sci Am, 1996, 275: 150-154.
[16] Strieter R M, Burdick M D,Gomperts B N, et al. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev, 2005, 16 (6): 593-609.
[17] M Numasaki, M Watanabe, T Suzuki, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR2-dependent angiogenesis. J Immunol, 2005, 175 (9): 6177-6189.
[18] Benjamin D. Zeitlin, Esther Joo, Zhihong Dong, et al. Antiangiogenic effect of TW37, a small molecule inhibitor of Bcl-2. Cancer Res, 2006, 66 (17): 8698-8706.
[19] Walz A.R, Burgener B.Car, M Baggiolini S, et al. Structure and neutrophil- activating properties of a novel inflammatory peptide-78 (ENA-78) with homology to Interleukin-8. Exp Med, 1991, 174: 1355-1362.
[20] Andrew C.Keats, Sarah Keats, John H, et al.ZBP-89, SP1 and nuclear factor-κB regulate epithelial nertrophil activating peptide-78 gene expression in caco-a human coloric epithelial cells. Biol Chem, 2001, 276(47): 43713-43722.
[21] John R, Judithann M, Peter R, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits Interleukin-8 induced neutrophil migration. J Biol Chemis. 1998,273(17): 10095-10098.
[22] P.H. SugdenA, Clerk, et al. Regulation of the ERK subgroup of MAP kinase cascades through G protein- coupled receptors, Cell Signal, 1997, 337-351.
[23] T. Pawson, J.D. Scott. Signaling through scaffold, anchoring, and adaptor proteins, Science, 1997, 278(5346): 2075-2080.
[24] V. Shyamala, H. Khoja, et al. Interleukin-8 receptors R1 and R2 activate mitogen-activated protein kinases and induce c-fos, independent of Ras and Raf-1 in Chinese hamster ovary cells. Biochemistry, 1998, 37(45): 15918-15924.
[25] J.P. Couty, M.C. Gershengorn, et al. Insights into the viral G protein-coupled receptor encoded by human herpesvirus type 8 (HHV-8). Biol Cell, 2004, 96(5): 349-354.
[26] S.K. Manna, G.T. Ramesh, et al. Interleukin-8 induces nuclear transcription factor-kappaB through a TRAF6-dependent pathway. Biol Chem, 2005, 280 (8): 7010-7021.
[27] MP Keane, JA Belperio, YY Xue,et al. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer, J Immunol, 2004, 172 (5): 2853-2860.
[28] J.L. Wu, T. Abe, R. Inoue, M. Fujiki, Kobayashi, et al. IkappaBalphaM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells, Neurol Res 2004,26. 785-791
[29] C Murphy, M McGurk, J Pettigrew, et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clinical Cancer Research, 2005, 11(11): 4117-4127.
[30] PJ Maxwell, R Gallagher, A Seaton, et al. HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene, 2007,26, 7333-7345.
[31] Jin Kim Sun, Hisanori Uehara, et al. Expression of lnterleukin-8 Correlates with Angiogenesis, Tumorigenicity, and Metastasis of Human Prostate Cancer Cells Implanted Orthotopically in Nude Mice. Neoplasia. 2001 January; 3(1): 33-42.
[32] C. T. Mierke, D. P. Zitterbart, P. Kollmannsberger, et al. Breakdown of the endothelial barrier function in tumor cell transmigration. Biophysical Journal, 2008, 94(7): 2832-2846.
[33] Reiland J, Furcht LT, McCarthy JB, et al. CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor. Prostate, 1999,41(2): 78-88
[1]Zlotnik A,Yoshie O.Chemokines:a new classification system and their role in immunity.Immunity,2000,12(2):121-127.
[2]Le Y,Zhou Y,Iribarren P,et al.Chemokines and chemokine receptors:their manifold Roles in Homeostasis and Disease.CellMol Immunol,2004,1(2):95-104.
[3]Strieter R M,Burdickm D,Gompert B N,et al.CXC chemokines in angiogenesis.Cytokine Growth Factor Rev,2005,16(6):593-609.
[4]Alain P.Vicari,Christophe Caux,et al.Chemokines in cancer.Cytokine and Growth Factor Reviews.2002,13:143-154
[5]Maureen N.Ajuebor,Mark G,et al.Swain Role of chemokines and chemokine receptors in the gastrointestinal tract.Immunology,2002,105:137-143.
[6]Kelner G.S,Kennedy J,Bacon K.B,et al.Lymphotactin:a cytokine that represents a new class of chemokine.Science,1994,266:1395-1399.
[7]Bazan,J.F.,Bacon,K.B.,Hardiman,G,et al.A new class of membrane-bound chemokine with a CX3C motif.Nature,1997,385:640-644.
[8] Yuan GH, Masuko-Hongo K, Nishioka K, et al. Role of Chemokines/ Chemokine Receptor Systems in Cartilage Degradation. Drug News Perspect, 2001,14(10): 591-600.
[9] Murphy PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev, 2002, 54 (2): 227 - 229.
[10] Wurbel MA, Malissen M, Guy-Grand D, et al. Impaired accumulation of antigen-specific CD8 lymphocytes in chemokine CCL25-deficient intestinal epithelium and lamina propria. J Immunol, 2007,178 (12): 7598-7606
[11] Bono MR, Elgueta R, Sauma D, et al. The essential role of chemokines in the selective regulation of lymphocyte homing. Cytokine Growth Factor Rev, 2007, 18 (1-2): 33-43.
[12] G Muller, UE Hopken, M Lipp. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev, 2003, 195 (10): 117 -135
[13] Lukacs-Kornek V, Engel D, Tacke F, et al. The role of chemokines and their receptors in dendritic cell biology. Front Biosci, 2008, 13 (1): 2238 - 2252.
[14] Z Brown, ME Gerritsen, WW Carley, et al. Chemokine gene expression and secretion by cytokine-activated human microvascular endothelial cells. Differential regulation of monocyte chemoattractant protein-1 and interleukin-8 in response to interferon-gamma. American Journal of Pathology, 1994, 145: 913-921
[15] Ransohoff R M. Chemokines and chemokine receptors in model neurological pathologies: molecular and immunocytochemical approaches. Meth. Enzymol. 1997,287:319-348.
[16] Karpus W J, Kennedy K J. MIP-1α and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J. Leukoc. Biol. 1997, 62: 681-687.
[17] Glabinski AR, Tani, M, Tuohy V K, Tuthill R J et al. Central nervous system chemokine mRNA accumulation follows initial leukocyte entry at the onset of acute murine experimental autoimmune encephalomyelitis. Brain. Behav. Immunol. 1995,9:315-330.
[18] Karpus W J, et al. An important role for the chemokine macrophage inflammatory protein-1 α in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J. Immunol. 1995, 155: 5003-5010.
[19] Godiska R, Chantry D, Dietsch G N, et al. Chemokine expression in murine experimental allergic encephalomyelitis. J. Neuroimmunol. 1995, 58:167-176
[20] Ransohoff R M. et al. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J. 1993, 7, 592-600.
[21] Miyagishi R, Kikuchi S, Fukazawa T, et al. Macrophage inflammatory protein-1 α in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J. Neurol. Sci. 1995, 129,223-227
[22] Gu L, et al. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000,404,407-411.
[23] Streblow D N. et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell, 1999,99: 511-520.
[24] Gu L, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell, 1998,2:275-281.
[25] Gosling J. et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest, 1999, 103: 773-778.
[26] Feng Y, Broder C C, Kennedy P E, et al. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 1996,272: 872-877.
[27] Berger EA, Murphy P M, Farber J M, et al. Chemokine receptos as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 1999, 17: 657-700.
[28] Wu L, et al. CD4-induced interaction of primary HIV-1 gpl20 glycoproteins with the chemokine receptor CCR-5. Nature, 1996, 384: 179-183.
[29] Trkola A. et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature, 1996, 384: 184-187.
[30] Blanpain C. et al. Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood, 2000, 96: 1638-1645.
[31] Palacios E. et al. Parallel evolution of CCR5-null phenotypes in humans and in a natural host of simian immunodeficiency virus. Curr. Biol.1998, 8: 943-946.
[32] R Salcedo, JJ Oppenheim. Role of chemokines in angiogenesis: CXCL12/ SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation, 2003,10(3-4):359 - 370.
[33] Mehrad B, KeaneMP, Strieter RM. Chemokines as mediators of angiogenesis. Thromb Haemost, 2007, 97 (5): 755 - 62
[34] Alain P. Vicari, Christophe Caux. Chemokines in cancer. Cytokine & Growth Factor Reviews,2002 (13): 143-154
[35] Balkwill F, Montovani A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357(9255): 539-545.
[36] Schmausser B, Endrich S, Brandlein S, et al. The chemokine receptor CCR7 is expressed on epithelium of non-inflamed gastric mucosa, Helicobacter pylori gastritic, gastric carcinoma and its precursor lesions and up-regulated by H pylori. Clin Exp Immimol, 2005,139: 323-327.
[37] Ottaiano A, di Palma A, Napolitano M, et al. Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells.Cancer Immunol Immunother, 2005, 54: 781-791.
[38] Xu Y, Zhang SZ, Huang Pc, et al. Expression of chemokine receptor CXCR4 in nasopharyngeal carcinoma cells. Ai zheng 2004,23: 136-140.
[39] Brigati C, Noonan DM, Albini A, et al. Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis, 2002,19: 247-258
[40] Owen JD, Strieter R, Burdick M, et al. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity / growth-regulated cytokine beta and gamma proteins. Int J Cancer, 1997, 73: 94-103
[41] Folkman J. Tumor angiogenesis: therapeutic implication. N Engl J Med, 1971, 285 (21): 1182-1186.
[42] Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 1994, 79 (2): 185-188.
[43] Folkman J. The vascularization of tumors. Sci Am, 1976, 234(5): 58-64, 70-73.
[44] Folkman J. Fighting cancer by attacking its blood supply. Sci Am, 1996, 275: 150-154.
[45] Schimanski CC, Schwald S, Simiantonaki N, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res, 2005, 11(5): 1743-1750.
[46] Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor4/ stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res, 2005,11(2 Pt 1): 490-497.
[47] Li F, Zhu HS, Han ZQ, et al. Effects of chemokine receptor and its ligand on migration of ovarian cancer cells. Ai Zheng, 2005,24(1): 23-27
[48] Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res, 2002, 62(24): 7328-7334.
[49] Su L, Zhang J, Xu H, et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res, 2005,11(23): 8273-8280.
[50] Ahmedin Jemal, Rebecca Siegel, et al Cancer Statistics, 2008 CA Cancer J Clin, 2008, 58:71-96.
[51] 孙颖浩. 前列腺癌诊断与治疗现状. 实用老年医学2005,19(4): 179-181.
[52] Loberg RD, Day LL, Harwood J, et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia. 2006, 8(7): 578-586
[53] Loberg RD, Ying C, Craig M, et al. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia, 2007, 9: 556-562.
[54] Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate, 2006, 66: 124-134.
[55] J Wang, M Huang, P Lee, et al. Interleukin-8 inhibits non-small cell lung cancer proliferation: a possible role for regulation of tumor growth by autocrine and paracrine pathways.J Interferon & Cytokine Res,1996,16(1):53-60
[56]Kido S,Kitadai Y,Hattori N,et al.Interleukin 8 and vascular endothelial growth factor prognostic factors in human gastric carcinomas.Eur Cancer,2001,37(12):1482.
[57]Li-Fen Lee,Ronald P.Hellendall,et al.IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration.J Immunology,2000,164:2769-2775.
[58]Jin Kim Sun,Hisanori Uehara,et al.Expression of interleukin-8 correlates with angiogenesis,yumorigenicity,and metastasis of human prostate cancer cells implanted orthotopically in nude mice.Neoplasia.2001 Jan,3(1):33-42
[59]Inoue K,Slaton JW,Eve BY,et al.Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.Clin Cancer Res,2000,6(5):2104-2119.
[60]Shinako Araki,Yohei Omori,Dominie Lyn,et al.Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer.Cancer Res,2007,67(14):6854-6862.
[61]ML Nagpal,J Davis,T Lin,et al.Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor(CXCR3) expression and inhibits cell proliferation.Molecular Basis of Disease,2006,1762(9):811-818.
[62]Merav DH,E Pikarsky,R Abramovitch,et al.Role of high expression levels of CXCR4 in tumor growth,vascularization,and metastasis.FASEB Journal.2004,18:1240-1242
[63]Taichman RS,Cooper C,Keller ET,et al.Use of the stromal cell- derived factor-1/ CXCR4 pathway in prostate cancer metastasis to bone.Cancer Research,2002,62:1832-1837.
[64]张冉,王栋,王菊蓉等.CXCR4在前列腺癌组织中的表达与意义.第二军医大学学报,2006 Sep,27(9),965-968.
[65]Robert D.Loberg,Chi Ying,Matt Craig,et al.Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.Cancer Research,2007,67,9417-9424
[66]Juarez J,Bradstock KF,Gottlieb DJ,et al.Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cell in vitro. Leukemia (Baltimore), 2003,17: 1294-1300.
[67] Scotton CJ, Wilson JL, Scott KA, et al .Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Research, 2002, 62: 5930-5938.
[68] Hendrix CW, Flexner C, Macfarland RT, et al. Pharmacokinetics and safety of AMD3100, a novel antagonist of the CXCR - 4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother, 2000, 44: 1667-1673.
[2]孙颖浩.前列腺癌诊断与治疗现状.实用老年医学,2005,19(4):179-11.
[3]Ajuebor MN,Swain MG,Perretti M,et al.Chemokines as novel therapeutic target s in inflammatory diseases.Biochem Pharmacol,2002,63(7):1191.
[4]Alain P.Vicari,Christophe Caux.Chemokines in cancer.Cytokine & Growth Factor Reviews,2002,13:143-154.
[5]Walz A,Burgener R,Car B,Baggiolini M,Kunkel SL,Strieter RM.Structure and neutrophil-activating properties of a novel inflammatory peptide(ENA-78)with homology to interleukin 8.J Exp Med.1991,174(6):1355-1362.
[6]Arenberg DA,Keane MP,et al.Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer.J Clin Invest,1998,102(3):465-472.
[7]Frick VO,et al.Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases.Pancreatology,2008,8(4-5):488-497.
[8]Wong YF,Cheung TH,Lo KW,Yim SF,Siu NS,Chan SC,Ho TW,Wong KW,Yu MY,Wang VW,et al.Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling.Oncogene,2007,26:1971-1982.
[9]Miyazaki H,Patel V,Wang H,Ensley JF,Gutkind JS,and Yeudall WA.Growth factor-sensitive molecular targets identified in primary and metastatic head and neck squamous cell carcinoma using microarray analysis.Oral Oncol,2006,42(3):240-256.
[10]Miyazaki H,Patel V,Wang H,Edmunds RK,Gutkind JS,and Yeudall WA.Down-regulation of CXCL5 inhibits squamous carcinogenesis.Cancer Res,2006,66(8):4279-4284.
[11]Park JY,Park KH,Bang S,Kim MH,Lee JE,Gang J,Koh SS,and Song SY,CXCL5 overexpression is associated with late stage gastric cancer.J Cancer Res Clin Oncol,2007,133(11):835-840.
[12] Folkman J. Tumor angiogenesis: therapeutic implication. N Engl J Med, 1971, 285 (21): 1182-1186.
[13] Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 1994, 79 (2): 185-188.
[14] Folkman J. The vascularization of tumors. Sci Am, 1976,234(5): 58-64, 70-73.
[15] Folkman J. Fighting cancer by attacking its blood supply. Sci Am, 1996, 275: 150-154.
[16] Strieter R M, Burdick M D,Gomperts B N, et al. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev, 2005, 16 (6): 593-609.
[17] M Numasaki, M Watanabe, T Suzuki, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR2-dependent angiogenesis. J Immunol, 2005, 175 (9): 6177-6189.
[18] Benjamin D. Zeitlin, Esther Joo, Zhihong Dong, et al. Antiangiogenic effect of TW37, a small molecule inhibitor of Bcl-2. Cancer Res, 2006, 66 (17): 8698-8706.
[19] Walz A.R, Burgener B.Car, M Baggiolini S, et al. Structure and neutrophil- activating properties of a novel inflammatory peptide-78 (ENA-78) with homology to Interleukin-8. Exp Med, 1991, 174: 1355-1362.
[20] Andrew C.Keats, Sarah Keats, John H, et al.ZBP-89, SP1 and nuclear factor-κB regulate epithelial nertrophil activating peptide-78 gene expression in caco-a human coloric epithelial cells. Biol Chem, 2001, 276(47): 43713-43722.
[21] John R, Judithann M, Peter R, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits Interleukin-8 induced neutrophil migration. J Biol Chemis. 1998,273(17): 10095-10098.
[22] P.H. SugdenA, Clerk, et al. Regulation of the ERK subgroup of MAP kinase cascades through G protein- coupled receptors, Cell Signal, 1997, 337-351.
[23] T. Pawson, J.D. Scott. Signaling through scaffold, anchoring, and adaptor proteins, Science, 1997, 278(5346): 2075-2080.
[24] V. Shyamala, H. Khoja, et al. Interleukin-8 receptors R1 and R2 activate mitogen-activated protein kinases and induce c-fos, independent of Ras and Raf-1 in Chinese hamster ovary cells. Biochemistry, 1998, 37(45): 15918-15924.
[25] J.P. Couty, M.C. Gershengorn, et al. Insights into the viral G protein-coupled receptor encoded by human herpesvirus type 8 (HHV-8). Biol Cell, 2004, 96(5): 349-354.
[26] S.K. Manna, G.T. Ramesh, et al. Interleukin-8 induces nuclear transcription factor-kappaB through a TRAF6-dependent pathway. Biol Chem, 2005, 280 (8): 7010-7021.
[27] MP Keane, JA Belperio, YY Xue,et al. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer, J Immunol, 2004, 172 (5): 2853-2860.
[28] J.L. Wu, T. Abe, R. Inoue, M. Fujiki, Kobayashi, et al. IkappaBalphaM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells, Neurol Res 2004,26. 785-791
[29] C Murphy, M McGurk, J Pettigrew, et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clinical Cancer Research, 2005, 11(11): 4117-4127.
[30] PJ Maxwell, R Gallagher, A Seaton, et al. HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene, 2007,26, 7333-7345.
[31] Jin Kim Sun, Hisanori Uehara, et al. Expression of lnterleukin-8 Correlates with Angiogenesis, Tumorigenicity, and Metastasis of Human Prostate Cancer Cells Implanted Orthotopically in Nude Mice. Neoplasia. 2001 January; 3(1): 33-42.
[32] C. T. Mierke, D. P. Zitterbart, P. Kollmannsberger, et al. Breakdown of the endothelial barrier function in tumor cell transmigration. Biophysical Journal, 2008, 94(7): 2832-2846.
[33] Reiland J, Furcht LT, McCarthy JB, et al. CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor. Prostate, 1999,41(2): 78-88
[1]Zlotnik A,Yoshie O.Chemokines:a new classification system and their role in immunity.Immunity,2000,12(2):121-127.
[2]Le Y,Zhou Y,Iribarren P,et al.Chemokines and chemokine receptors:their manifold Roles in Homeostasis and Disease.CellMol Immunol,2004,1(2):95-104.
[3]Strieter R M,Burdickm D,Gompert B N,et al.CXC chemokines in angiogenesis.Cytokine Growth Factor Rev,2005,16(6):593-609.
[4]Alain P.Vicari,Christophe Caux,et al.Chemokines in cancer.Cytokine and Growth Factor Reviews.2002,13:143-154
[5]Maureen N.Ajuebor,Mark G,et al.Swain Role of chemokines and chemokine receptors in the gastrointestinal tract.Immunology,2002,105:137-143.
[6]Kelner G.S,Kennedy J,Bacon K.B,et al.Lymphotactin:a cytokine that represents a new class of chemokine.Science,1994,266:1395-1399.
[7]Bazan,J.F.,Bacon,K.B.,Hardiman,G,et al.A new class of membrane-bound chemokine with a CX3C motif.Nature,1997,385:640-644.
[8] Yuan GH, Masuko-Hongo K, Nishioka K, et al. Role of Chemokines/ Chemokine Receptor Systems in Cartilage Degradation. Drug News Perspect, 2001,14(10): 591-600.
[9] Murphy PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev, 2002, 54 (2): 227 - 229.
[10] Wurbel MA, Malissen M, Guy-Grand D, et al. Impaired accumulation of antigen-specific CD8 lymphocytes in chemokine CCL25-deficient intestinal epithelium and lamina propria. J Immunol, 2007,178 (12): 7598-7606
[11] Bono MR, Elgueta R, Sauma D, et al. The essential role of chemokines in the selective regulation of lymphocyte homing. Cytokine Growth Factor Rev, 2007, 18 (1-2): 33-43.
[12] G Muller, UE Hopken, M Lipp. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev, 2003, 195 (10): 117 -135
[13] Lukacs-Kornek V, Engel D, Tacke F, et al. The role of chemokines and their receptors in dendritic cell biology. Front Biosci, 2008, 13 (1): 2238 - 2252.
[14] Z Brown, ME Gerritsen, WW Carley, et al. Chemokine gene expression and secretion by cytokine-activated human microvascular endothelial cells. Differential regulation of monocyte chemoattractant protein-1 and interleukin-8 in response to interferon-gamma. American Journal of Pathology, 1994, 145: 913-921
[15] Ransohoff R M. Chemokines and chemokine receptors in model neurological pathologies: molecular and immunocytochemical approaches. Meth. Enzymol. 1997,287:319-348.
[16] Karpus W J, Kennedy K J. MIP-1α and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J. Leukoc. Biol. 1997, 62: 681-687.
[17] Glabinski AR, Tani, M, Tuohy V K, Tuthill R J et al. Central nervous system chemokine mRNA accumulation follows initial leukocyte entry at the onset of acute murine experimental autoimmune encephalomyelitis. Brain. Behav. Immunol. 1995,9:315-330.
[18] Karpus W J, et al. An important role for the chemokine macrophage inflammatory protein-1 α in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J. Immunol. 1995, 155: 5003-5010.
[19] Godiska R, Chantry D, Dietsch G N, et al. Chemokine expression in murine experimental allergic encephalomyelitis. J. Neuroimmunol. 1995, 58:167-176
[20] Ransohoff R M. et al. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J. 1993, 7, 592-600.
[21] Miyagishi R, Kikuchi S, Fukazawa T, et al. Macrophage inflammatory protein-1 α in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J. Neurol. Sci. 1995, 129,223-227
[22] Gu L, et al. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000,404,407-411.
[23] Streblow D N. et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell, 1999,99: 511-520.
[24] Gu L, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell, 1998,2:275-281.
[25] Gosling J. et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest, 1999, 103: 773-778.
[26] Feng Y, Broder C C, Kennedy P E, et al. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 1996,272: 872-877.
[27] Berger EA, Murphy P M, Farber J M, et al. Chemokine receptos as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 1999, 17: 657-700.
[28] Wu L, et al. CD4-induced interaction of primary HIV-1 gpl20 glycoproteins with the chemokine receptor CCR-5. Nature, 1996, 384: 179-183.
[29] Trkola A. et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature, 1996, 384: 184-187.
[30] Blanpain C. et al. Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood, 2000, 96: 1638-1645.
[31] Palacios E. et al. Parallel evolution of CCR5-null phenotypes in humans and in a natural host of simian immunodeficiency virus. Curr. Biol.1998, 8: 943-946.
[32] R Salcedo, JJ Oppenheim. Role of chemokines in angiogenesis: CXCL12/ SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation, 2003,10(3-4):359 - 370.
[33] Mehrad B, KeaneMP, Strieter RM. Chemokines as mediators of angiogenesis. Thromb Haemost, 2007, 97 (5): 755 - 62
[34] Alain P. Vicari, Christophe Caux. Chemokines in cancer. Cytokine & Growth Factor Reviews,2002 (13): 143-154
[35] Balkwill F, Montovani A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357(9255): 539-545.
[36] Schmausser B, Endrich S, Brandlein S, et al. The chemokine receptor CCR7 is expressed on epithelium of non-inflamed gastric mucosa, Helicobacter pylori gastritic, gastric carcinoma and its precursor lesions and up-regulated by H pylori. Clin Exp Immimol, 2005,139: 323-327.
[37] Ottaiano A, di Palma A, Napolitano M, et al. Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells.Cancer Immunol Immunother, 2005, 54: 781-791.
[38] Xu Y, Zhang SZ, Huang Pc, et al. Expression of chemokine receptor CXCR4 in nasopharyngeal carcinoma cells. Ai zheng 2004,23: 136-140.
[39] Brigati C, Noonan DM, Albini A, et al. Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis, 2002,19: 247-258
[40] Owen JD, Strieter R, Burdick M, et al. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity / growth-regulated cytokine beta and gamma proteins. Int J Cancer, 1997, 73: 94-103
[41] Folkman J. Tumor angiogenesis: therapeutic implication. N Engl J Med, 1971, 285 (21): 1182-1186.
[42] Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 1994, 79 (2): 185-188.
[43] Folkman J. The vascularization of tumors. Sci Am, 1976, 234(5): 58-64, 70-73.
[44] Folkman J. Fighting cancer by attacking its blood supply. Sci Am, 1996, 275: 150-154.
[45] Schimanski CC, Schwald S, Simiantonaki N, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res, 2005, 11(5): 1743-1750.
[46] Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor4/ stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res, 2005,11(2 Pt 1): 490-497.
[47] Li F, Zhu HS, Han ZQ, et al. Effects of chemokine receptor and its ligand on migration of ovarian cancer cells. Ai Zheng, 2005,24(1): 23-27
[48] Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res, 2002, 62(24): 7328-7334.
[49] Su L, Zhang J, Xu H, et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res, 2005,11(23): 8273-8280.
[50] Ahmedin Jemal, Rebecca Siegel, et al Cancer Statistics, 2008 CA Cancer J Clin, 2008, 58:71-96.
[51] 孙颖浩. 前列腺癌诊断与治疗现状. 实用老年医学2005,19(4): 179-181.
[52] Loberg RD, Day LL, Harwood J, et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia. 2006, 8(7): 578-586
[53] Loberg RD, Ying C, Craig M, et al. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia, 2007, 9: 556-562.
[54] Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate, 2006, 66: 124-134.
[55] J Wang, M Huang, P Lee, et al. Interleukin-8 inhibits non-small cell lung cancer proliferation: a possible role for regulation of tumor growth by autocrine and paracrine pathways.J Interferon & Cytokine Res,1996,16(1):53-60
[56]Kido S,Kitadai Y,Hattori N,et al.Interleukin 8 and vascular endothelial growth factor prognostic factors in human gastric carcinomas.Eur Cancer,2001,37(12):1482.
[57]Li-Fen Lee,Ronald P.Hellendall,et al.IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration.J Immunology,2000,164:2769-2775.
[58]Jin Kim Sun,Hisanori Uehara,et al.Expression of interleukin-8 correlates with angiogenesis,yumorigenicity,and metastasis of human prostate cancer cells implanted orthotopically in nude mice.Neoplasia.2001 Jan,3(1):33-42
[59]Inoue K,Slaton JW,Eve BY,et al.Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.Clin Cancer Res,2000,6(5):2104-2119.
[60]Shinako Araki,Yohei Omori,Dominie Lyn,et al.Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer.Cancer Res,2007,67(14):6854-6862.
[61]ML Nagpal,J Davis,T Lin,et al.Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor(CXCR3) expression and inhibits cell proliferation.Molecular Basis of Disease,2006,1762(9):811-818.
[62]Merav DH,E Pikarsky,R Abramovitch,et al.Role of high expression levels of CXCR4 in tumor growth,vascularization,and metastasis.FASEB Journal.2004,18:1240-1242
[63]Taichman RS,Cooper C,Keller ET,et al.Use of the stromal cell- derived factor-1/ CXCR4 pathway in prostate cancer metastasis to bone.Cancer Research,2002,62:1832-1837.
[64]张冉,王栋,王菊蓉等.CXCR4在前列腺癌组织中的表达与意义.第二军医大学学报,2006 Sep,27(9),965-968.
[65]Robert D.Loberg,Chi Ying,Matt Craig,et al.Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.Cancer Research,2007,67,9417-9424
[66]Juarez J,Bradstock KF,Gottlieb DJ,et al.Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cell in vitro. Leukemia (Baltimore), 2003,17: 1294-1300.
[67] Scotton CJ, Wilson JL, Scott KA, et al .Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Research, 2002, 62: 5930-5938.
[68] Hendrix CW, Flexner C, Macfarland RT, et al. Pharmacokinetics and safety of AMD3100, a novel antagonist of the CXCR - 4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother, 2000, 44: 1667-1673.